AAD 2020: Risankizumab Demonstrates Superiority to Secukinumab for Psoriasis in Head-to-Head Trial
Safety of both agents was consistent with previous findings
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.